ImmuneSensor Therapeutics, Inc.

DALLAS, TX · Founded 2019 · Biotech · Private

Therapeutics that harness the innate immune system to treat inflammation, autoimmune disease, and cancer

Claim this profile

Follows are private to you and power your alerts

Updated · immunesensor.com

Sector
Biotech
Headquarters
DALLAS, TX
Founded
2019
Latest Form D
$10M, Dec 2022
Total capital
$10M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$10M
1 Form D · last Dec 2022
47 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
0
4 pending

Capital timeline

2022FEDERAL ↑EQUITY ↓Cumulative $10M1st Form D$10M
2022FEDERAL ↑EQUITY ↓Cumulative $10M1st Form D$10M

Latest events

  • Private capital raisedForm D · SEC · 1st filing$10M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Founders and team

From SEC Form D filings
  • Ernest WongExecutive Officer, DirectorNamed in SEC Form D filings
  • Ning ZhangDirectorNamed in SEC Form D filings
  • Qingsong LiExecutive Officer, DirectorNamed in SEC Form D filings
  • Zhi HongDirectorNamed in SEC Form D filings

What it has protected

USPTO · 0 granted of 4
  • PendingSolid Forms And Salts Of A Quinoline Cgas Antagonist CompoundUSPTOApplication PCTUS2025044499
  • PendingSOLID FORMS AND SALTS OF A QUINOLINE cGAS ANTAGONIST COMPOUNDUSPTOApplication 63689562
  • PendingQuinoline Cgas Antagonist CompoundsUSPTOApplication PCTUS2023063623
Show all 4 patent records
  • Solid Forms And Salts Of A Quinoline Cgas Antagonist CompoundApplication PCTUS2025044499Pending
  • SOLID FORMS AND SALTS OF A QUINOLINE cGAS ANTAGONIST COMPOUNDApplication 63689562Pending
  • Quinoline Cgas Antagonist CompoundsApplication PCTUS2023063623Pending
  • cGAS ANTAGONIST COMPOUNDSApplication 62355403Pending

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .